Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

A0593

Sigma-Aldrich

Alprostadil

meets USP testing specifications

Synonym(s):

Prostaglandin E1, (11α,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid, Alprostadil, PGE1

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C20H34O5
CAS Number:
745-65-3
Molecular Weight:
354.48
Beilstein:
5294062
EC Number:
212-017-2
MDL number:
MFCD00077860
UNSPSC Code:
12352200
PubChem Substance ID:
24890439
Pricing and availability is not currently available.

Agency

meets USP testing specifications

Assay

95.0-105.0% dry basis

form

powder

functional group

carboxylic acid

storage temp.

−20°C

SMILES string

O=C1[C@H](CCCCCCC(O)=O)[C@@H](/C=C/[C@H](CCCCC)O)[C@H](O)C1

InChI

1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1

InChI key

GMVPRGQOIOIIMI-DWKJAMRDSA-N

Gene Information

human ... PTGER1(5731) , PTGER2(5732) , PTGIR(5739)
mouse ... Ptger1(19216) , Ptger2(19217) , Ptger3(19218) , Ptger4(19219)

Looking for similar products? Visit Product Comparison Guide

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301

Precautionary Statements

P301 + P310 + P330

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCBM4060
BCBM1260
SLBH2707V
SLBG4895V
SLBD1207V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pierre Costa et al.
Drugs, 72(17), 2243-2254 (2012-11-23)
The global burden of erectile dysfunction (ED) is increasing. It is estimated that 8-19% of men in Europe have ED and that by 2025 the prevalence of ED worldwide will reach 322 million. The gold standard therapy for ED is
A Creutzig et al.
VASA. Zeitschrift fur Gefasskrankheiten, 33(3), 137-144 (2004-10-06)
The relevance of Prostaglandin El (PGE,) in the treatment of peripheral arterial occlusive disease stage III and IV was to be evaluated for the first time by a meta-analysis. Altogether, 643 patients were analyzed from seven randomized, controlled PGE1 studies
Michael Berner et al.
The journal of sexual medicine, 9(12), 3089-3107 (2012-10-24)
As yet, a summary of research evidence concerning the efficacy of psychological treatment in male sexual dysfunction is lacking. Our systematic review gives an overview of the efficacy of psychosocial interventions in all male sexual dysfunctions. Main outcome measures included
J G Ray
Transplantation, 66(4), 476-483 (1998-09-12)
To assess whether prostaglandin E1 analogs have a role in either reducing renal allograft rejection or improving renal function among both transplant and nontransplant patients. Studies were identified through Ovid MEDLINE between 1981 and December 1997 using multiple MeSH headings
Mikkel Fode et al.
BJU international, 112(7), 998-1008 (2013-07-06)
The pathophysiology of erectile dysfunction after radical prostatectomy (RP) is believed to include neuropraxia, which leads to temporarily reduced oxygenation and subsequent structural changes in penile tissue. This results in veno-occlusive dysfunction, therefore, penile rehabilitation programmes focus on tissue oxygenation.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service